Creative Planning Grows Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Creative Planning grew its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 40.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,935 shares of the medical device company’s stock after purchasing an additional 3,461 shares during the quarter. Creative Planning’s holdings in Tandem Diabetes Care were worth $481,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Tandem Diabetes Care by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 7,021,906 shares of the medical device company’s stock worth $207,708,000 after acquiring an additional 18,571 shares during the period. PNC Financial Services Group Inc. raised its position in shares of Tandem Diabetes Care by 79.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,788 shares of the medical device company’s stock valued at $171,000 after buying an additional 2,562 shares during the last quarter. GAMMA Investing LLC lifted its position in Tandem Diabetes Care by 55.7% during the first quarter. GAMMA Investing LLC now owns 3,845 shares of the medical device company’s stock worth $136,000 after buying an additional 1,375 shares during the period. Park Avenue Securities LLC grew its holdings in Tandem Diabetes Care by 20.3% in the first quarter. Park Avenue Securities LLC now owns 8,650 shares of the medical device company’s stock valued at $306,000 after purchasing an additional 1,459 shares during the period. Finally, MCF Advisors LLC increased its holdings in shares of Tandem Diabetes Care by 79.3% during the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after buying an additional 445 shares during the last quarter.

Tandem Diabetes Care Trading Up 0.7 %

Tandem Diabetes Care stock opened at $37.61 on Wednesday. Tandem Diabetes Care, Inc. has a 12 month low of $13.82 and a 12 month high of $53.69. The company has a quick ratio of 2.38, a current ratio of 3.05 and a debt-to-equity ratio of 1.31. The business has a 50 day moving average price of $42.05 and a two-hundred day moving average price of $41.92. The stock has a market cap of $2.43 billion, a price-to-earnings ratio of -17.33 and a beta of 1.33.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.07. Tandem Diabetes Care had a negative return on equity of 41.54% and a negative net margin of 17.15%. The firm had revenue of $221.90 million for the quarter, compared to analysts’ expectations of $205.63 million. During the same period in the prior year, the business posted ($0.30) earnings per share. The business’s revenue was up 13.3% compared to the same quarter last year. As a group, equities analysts forecast that Tandem Diabetes Care, Inc. will post -1.76 EPS for the current year.

Analysts Set New Price Targets

TNDM has been the subject of a number of recent research reports. Morgan Stanley reiterated an “equal weight” rating and issued a $45.00 target price on shares of Tandem Diabetes Care in a research note on Monday, September 23rd. Royal Bank of Canada assumed coverage on Tandem Diabetes Care in a research note on Wednesday, October 2nd. They set an “outperform” rating and a $65.00 target price on the stock. Piper Sandler reissued an “overweight” rating and issued a $55.00 price objective (up previously from $50.00) on shares of Tandem Diabetes Care in a research note on Friday, August 2nd. Canaccord Genuity Group started coverage on Tandem Diabetes Care in a research report on Thursday, August 8th. They set a “buy” rating and a $57.00 price objective for the company. Finally, Wells Fargo & Company increased their target price on Tandem Diabetes Care from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of “Moderate Buy” and a consensus target price of $55.13.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.